M&A Deal Summary

Bain Capital Private Equity Acquires Centrient Pharmaceuticals

On June 29, 2018, private equity firm Bain Capital Private Equity acquired life science company Centrient Pharmaceuticals from DSM-Firmenich and Sinochem Group

Acquisition Highlights
  • This is Bain Capital Private Equity’s 10th transaction in the Life Science sector.
  • This is Bain Capital Private Equity’s 5th transaction in the Netherlands.

M&A Deal Summary

Date 2018-06-29
Target Centrient Pharmaceuticals
Sector Life Science
Buyer(s) Bain Capital Private Equity
Sellers(s) DSM-Firmenich
Sinochem Group
Deal Type Divestiture

Target

Centrient Pharmaceuticals

Rotterdam, Netherlands
Centrient Pharmaceuticals is a provider of sustainable antibiotics, next-generation statins and anti-fungals. Centrient develops, produces and sells intermediates, active pharmaceutical ingredients and finished dosage form pharmaceuticals. Centrient Pharmaceuticals is based in Rotterdam, Netherlands.

Search 201,157 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Bain Capital Private Equity

Boston, Massachusetts, United States

Investor Investor Investor Investor Investor


Category Private Equity Firm
Founded 1984
PE ASSETS 44.2B USD
Size Mega
Type Sector Agnostic
DESCRIPTION

Bain Capital Private Equity (BCPE), is the private equity investment arm of alternative asset management firm, Bain Capital. BCPE targets leveraged buyout and growth capital transactions in a wide variety of industries including information technology, communications, media, healthcare, industrial/manufacturing, retail/consumer, and financial services. Bain Capital is based in Boston with additional offices in New York, London, Mumbai, Hong Kong, Shanghai, Tokyo, and Munich.


DEAL STATS #
Overall 174 of 236
Sector (Life Science) 10 of 11
Type (Divestiture) 31 of 37
Country (Netherlands) 5 of 6
Year (2018) 7 of 12
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2018-06-28 Italmatch

Genoa, Italy

Italmatch is a chemical group, specialized in performance additives for water treatment, oil & gas, lubricants and plastics, and boasts a wide product range able to fulfil the requirements of the most demanding applications, including personal care. Italmatch was founded in 1997 and is based in Genoa, Italy.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2018-07-24 TriTech Software Systems

San Diego, California, United States

TriTech Software Systems is a provider of enterprise and mobile communication software and services to public safety customers. TriTech’s solutions are used by 911 call centers and police, fire and emergency medical services agencies to respond to, process, dispatch and communicate emergency responses.

Sell -

Seller(S) 2

SELLER

DSM-Firmenich

Kaiseraugst, Switzerland

Category Company
Founded 1902
Sector Chemicals
Employees27,926
Revenue 10.6B EUR (2023)
DESCRIPTION

DSM-Firmenich specializes in development, manufacture and marketing of performance materials, nutritional and pharmaceutical ingredients and industrial chemicals. The products are used in a wide range of end-markets and applications, such as human and animal nutrition and health, personal care, pharmaceuticals, automotive and transport, coatings and paint, housing and electrics & electronics. DSM-Firmenich founded in 1902 and is based in Kaiseraugst, Switzerland.


DEAL STATS #
Overall 13 of 17
Sector (Life Science) 2 of 3
Type (Divestiture) 12 of 16
Country (Netherlands) 7 of 9
Year (2018) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2017-12-22 BioCare Copenhagen A/S

Copenhagen, Denmark

BioCare Copenhagen A/S is a provider of probiotics and specialized in microbial actives with proven health benefits, targeting gastrointestinal disorders, metabolic disorders, infections, and immunity. BioCare Copenhagen A/S was established in 2012 and is based in Copenhagen, Denmark.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2020-02-19 Koninklijke DSM N.V. - BIO 300

Swaziland

Koninklijke DSM N.V. (Royal DSM) - BIO 300 is a clinical-stage drug under development to protect normal tissues from the harm caused by radiation. The drug’s radioprotective effects were originally discovered by researchers within the Department of Defense at the Armed Forces Radiobiology Research Institute.

Sell -
SELLER

Sinochem Group

Beijing, China

Category Company
Founded 1950
Sector Diversified
Employees46,225
DESCRIPTION

Sinochem Group Co., Ltd. is a diversified company. Sinochem Group has established five Strategic Business Units (SBU), namely energy, chemicals, agriculture, real estate and finance. Sinochem Group Co., Ltd. was founded in 1950 and is headquartered in Beijing, China.


DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Divestiture) 1 of 1
Country (Netherlands) 1 of 1
Year (2018) 1 of 1